Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Targeting CD47 and TNFAIP8 By Mir-155 Overcomes Drug Resistance and Inhibits Tumor Growth through Induction of Phagocytosis and Apoptosis in Multiple Myeloma

Nasrin Rastgoo, PhD, Jahangir Abdi, PhD, Maryam Pourabdollah, MD, Hong Chang, MD

Blood (2018) 132 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2018-99-113057

Published: 2018

Journal Articles

Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma

Lun Zhang, Nasrin Rastgoo, PhD, Maryam Pourabdollah, MD, Eldad Zacksenhaus, PhD, Yan Chen, MD PhD, Guoan Chen, MD, Hong Chang, MD

Blood (2018) 132 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2018-99-113026

Published: 2018

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma

Nasrin Rastgoo, PhD, Maryam Pourabdollah, MD, Jahangir Abdi, PhD BSc, MSc, Hong Chang, MD

Blood (2017) 130 (Supplement 1): 269.

https://doi.org/10.1182/blood.V130.Suppl_1.269.269

Published: 2017

Journal Articles

Coexistence of multiple myeloma and Paget disease of bone

Maryam Pourabdollah, Hong Chang

Blood (2017) 130 (9): 1173.

https://doi.org/10.1182/blood-2017-05-784199

Published: 2017

Journal Articles

Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance

Maryam Pourabdollah, Hong Chang

Blood (2017) 129 (7): 918.

https://doi.org/10.1182/blood-2016-10-745471

Published: 2017

Journal Articles

Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia

Maryam Pourabdollah, Hong Chang

Blood (2017) 129 (1): 132.

https://doi.org/10.1182/blood-2016-09-738021

Published: 2017

Journal Articles

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Maryam Pourabdollah, MD, Mohammad Bahmanyar, MD, Eshetu G Atenafu, MSc, PStat, Donna Reece, MD, Hong Chang, MD PhD

Blood (2016) 128 (22): 4506.

https://doi.org/10.1182/blood.V128.22.4506.4506

Published: 2016

NARROW

Targeting CD47 and TNFAIP8 By Mir-155 Overcomes Drug Resistance and Inhibits Tumor Growth through Induction of Phagocytosis and Apoptosis in Multiple Myeloma

Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma

Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma

Coexistence of multiple myeloma and Paget disease of bone

Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance

Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Targeting CD47 and TNFAIP8 By Mir-155 Overcomes Drug Resistance and Inhibits Tumor Growth through Induction of Phagocytosis and Apoptosis in Multiple Myeloma

Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma

Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma

Coexistence of multiple myeloma and Paget disease of bone

Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance

Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only